DOD Biotech Public Company Limited
DOD Biotech Public Company Limited, together with its subsidiaries, manufactures and distributes dietary supplements in Thailand. It offers dietary supplements for beauty and health in various forms comprising capsules, gels, jellies, powder, shot drinks, soft gels, tablets, probiotics, gummies, and direct-to-mouth. The company also provides food supplements and health drinks. In addition, it off… Read more
DOD Biotech Public Company Limited (DOD) - Total Liabilities
Latest total liabilities as of September 2025: ฿169.23 Million THB
Based on the latest financial reports, DOD Biotech Public Company Limited (DOD) has total liabilities worth ฿169.23 Million THB as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DOD Biotech Public Company Limited - Total Liabilities Trend (2013–2024)
This chart illustrates how DOD Biotech Public Company Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
DOD Biotech Public Company Limited Competitors by Total Liabilities
The table below lists competitors of DOD Biotech Public Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Willbes
KO:008600
|
Korea | ₩199.46 Billion |
|
Rigel Resource Acquisition Corp.
OTCGREY:RRACF
|
USA | $34.77 Million |
|
Tribeca Resources Corporation
PINK:TRRCF
|
USA | $210.11K |
|
China Yurun Food Group Limited
F:C7Y
|
Germany | €1.35 Billion |
|
Link Prop Investment AB
ST:LINKAB
|
Sweden | Skr220.20 Million |
|
Hwail Pharmaceutical Co.Ltd
KQ:061250
|
Korea | ₩5.29 Billion |
|
KRISHIVAL
NSE:KRISHIVAL
|
India | ₹479.20 Million |
|
Rcm Beteiligungs AG
F:RCMN
|
Germany | €28.48K |
Liability Composition Analysis (2013–2024)
This chart breaks down DOD Biotech Public Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DOD Biotech Public Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DOD Biotech Public Company Limited (2013–2024)
The table below shows the annual total liabilities of DOD Biotech Public Company Limited from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ฿394.40 Million | +4.45% |
| 2023-12-31 | ฿377.58 Million | -4.96% |
| 2022-12-31 | ฿397.29 Million | +8.93% |
| 2021-12-31 | ฿364.70 Million | -28.29% |
| 2020-12-31 | ฿508.55 Million | +51.20% |
| 2019-12-31 | ฿336.35 Million | +51.25% |
| 2018-12-31 | ฿222.39 Million | +106.69% |
| 2017-12-31 | ฿107.60 Million | +76.73% |
| 2016-12-31 | ฿60.88 Million | -34.05% |
| 2015-12-31 | ฿92.31 Million | +2531.96% |
| 2014-12-31 | ฿3.51 Million | 0.00% |
| 2013-12-31 | ฿3.51 Million | -- |